Agendia Building

Personalized Breast Cancer Workbook

No two tumors are alike. What are the characteristics of your breast cancer and how will that effect your treatment?

This worksheet will provide you with the questions that you need answered, so you and your physician can determine the best tools and treatment for your individual cancer.

Mi ficha personal de cáncer de mama >>



The majority of women with early-stage breast cancer have a Low Risk of cancer relapse based on genomic testing and may safely avoid chemotherapy.1  So how do you know if chemotherapy will benefit you? The MammaPrint 70-Gene Test is currently the only FDA-cleared test for risk of disease recurrence within five years for women of all ages. The test provides a personalized, binary result so you can know if you are Low Risk for cancer relapse – and not likely to show a significant benefit from chemotherapy.

1. Cardoso F, van’t Veer LJ, Bogaerts J et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016; 375:717-29.



MammaPrint: The clarity you need when it matters most.

You have just been diagnosed with cancer and it is a difficult time for you and your loved ones. You want control of the situation, clarity in your options and confidence in the treatment decision you make.
This video describes the path of three patients after their diagnosis and how MammaPrint test results helped inform them and their physician with their treatment management plans.


Join the Symphony Sisterhood.

Tens of thousands of breast cancer
patients are part of our community.

Visit our Facebook page today.